SoftOx Solutions AS (SOFTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, SoftOx Solutions AS (SOFTX) has a cash flow conversion efficiency ratio of -0.355x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Nkr-8.16 Million ≈ $-858.46K USD) by net assets (Nkr22.95 Million ≈ $2.42 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. View SoftOx Solutions AS stock price for real-time trading data and today's change.
SoftOx Solutions AS - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how SoftOx Solutions AS's cash flow conversion efficiency has evolved over time, based on yearly financial data. Also see SoftOx Solutions AS (SOFTX) total market value for the company's overall valuation and market capitalisation.
SoftOx Solutions AS Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SoftOx Solutions AS ranked by their cash flow conversion efficiency. Also see SoftOx Solutions AS (SOFTX) total assets for a full breakdown of the balance sheet.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Desoto Resources Ltd
AU:DES
|
-0.226x |
|
Ocean Vantage Holdings Bhd
KLSE:0220
|
-0.026x |
|
Park Street A/S
CO:PARKST-A
|
-0.014x |
|
Otto Holding AS
IS:OTTO
|
0.053x |
|
Good Way Technology Co Ltd
TWO:3272
|
0.056x |
|
Plus Therapeutics Inc
NASDAQ:PSTV
|
-0.522x |
|
Italian-Thai Development Public Company Limited
F:NYVF
|
0.490x |
|
Reka Industrial Oyj
HE:REKA
|
0.024x |
Annual Cash Flow Conversion Efficiency for SoftOx Solutions AS (2017–2025)
The table below shows the annual cash flow conversion efficiency of SoftOx Solutions AS from 2017 to 2025. Review how financially flexible is SoftOx Solutions AS to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Nkr22.95 Million ≈ $2.42 Million |
Nkr-18.87 Million ≈ $-1.99 Million |
-0.822x | -340.27% |
| 2024-12-31 | Nkr95.18 Million ≈ $10.02 Million |
Nkr32.56 Million ≈ $3.43 Million |
0.342x | +6.98% |
| 2023-12-31 | Nkr2.37 Million ≈ $249.01K |
Nkr756.68K ≈ $79.62K |
0.320x | +105.96% |
| 2022-12-31 | Nkr16.01 Million ≈ $1.68 Million |
Nkr-85.94 Million ≈ $-9.04 Million |
-5.369x | -557.42% |
| 2021-12-31 | Nkr88.85 Million ≈ $9.35 Million |
Nkr-72.56 Million ≈ $-7.64 Million |
-0.817x | -3.07% |
| 2020-12-31 | Nkr76.22 Million ≈ $8.02 Million |
Nkr-60.39 Million ≈ $-6.35 Million |
-0.792x | -548.68% |
| 2019-12-31 | Nkr86.47 Million ≈ $9.10 Million |
Nkr-10.56 Million ≈ $-1.11 Million |
-0.122x | +88.22% |
| 2018-12-31 | Nkr14.41 Million ≈ $1.52 Million |
Nkr-14.94 Million ≈ $-1.57 Million |
-1.037x | -81.43% |
| 2017-12-31 | Nkr26.85 Million ≈ $2.83 Million |
Nkr-15.34 Million ≈ $-1.61 Million |
-0.571x | -- |
About SoftOx Solutions AS
SoftOx Solutions AS, together with its subsidiaries, operates as a clinical-stage pharmaceutical company that anti-infective therapy for airway infections in Norway. The company develops SIS-03, a lead clinical program that is in phase 2a to treatment of chronic airway infections. It also developing pan antimicrobial pharmaceuticals targeting bacteria, viruses, yeast, spores, and fungi. SoftOx So… Read more